ClinicaliQ Trial Snapshot
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A — Recruiting • Phase III • NCT07416526.
- NXT007 compared to standard Factor VIII treatment for preventing bleeding in people with moderate-to-severe hemophilia A.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without inhibitors. The study will include people aged ≥12 years old with severe or moderate congenital hemophilia A without inhibitors on previous FVIII prophylaxis treatment. Conditions: Hemophilia A Interventions: NXT007, Human Coagulation Factor VIII Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 126 participants